Minimization of immunosuppression in kidney transplantation

Current Opinion in Nephrology and Hypertension

Volumn 16, Issue 6, 2007, Pages 535-541

  Augustine, Joshua J ^a   Hricik, Donald E ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Calcineurin inhibitors; Corticosteroids; Minimization

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID; THYMOCYTE ANTIBODY;

ANEMIA; CLINICAL TRIAL; DIARRHEA; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; PATIENT CARE; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; CALCINEURIN; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 37349040725     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3282f0b319     Document Type: Review

References (61)

1. Calne R, Moffatt SD, Friend PJ, et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999; 68:1613-1616.
2. Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation: efficacy and safety at five years. Am J Transplant 2005; 5:1347-1353.
3. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003; 76:120-129.
4. Knechtle SJ, Pirsch JD, Fechner JH, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3:722-730.
5. Tan HP, Kaczorowski DJ, Basu A, et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2006; 6:2409-3241.
6. Shapiro R, Zeevi A, Basu A, et al. Monitoring for donor-specific antibody (DSA) and outcomes after spaced weaning in adult renal transplant recipients [abstract]. Am J Transplant 2007; 7 (Suppl 2):200-201. A preliminary single center experience describing the problem of humoral immunity arising in patients treated with alemtuzumab and tacrolimus monotherapy.
7. Bodziak KA, Hricik DE. Minimizing the side effects of immunosuppression in kidney transplant recipients. Curr Opin Organ Transplant 2003; 8:160-166.
8. Augustine JJ, Hricik DE. Steroid sparing in kidney transplantation: changing paradigms, improving outcomes, and remaining questions. Clin J Am Soc Nephrol 2006; 1:1080-1089. A comprehensive review of recent steroid-free immunosuppression trials discussed in an historical context.
9. Cole E, Landsberg D, Russell D, et al. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation 2001; 72:845-850.
10. Birkeland SA. Steroid-free immunosuppression after kidney transplantation with antithymocyte globulin induction and cyclosporine and mycophenolate maintenance therapy. Transplantation 1998; 66:1207-1210.
11. Matas AJ, Kandaswamy R, Gillingham KJ, et al. Prednisone-free maintenance immunosuppression: a 5-year experience. Am J Transplant 2005; 5:2473-2478.
12. Kaufman DB, Leventhal JR, Axelrod D, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction: long-term results. Am J Transplant 2005; 5:2539-2548.
13. Vincenti F, Monaco A, Grinyo J, et al. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003; 3:306-311.
14. Schena FP, Vincenti F, Paraskevas S, et al., The FREEDOM Study Group. 12-month results of a prospective, randomized trial of steroid avoidance, steroid withdrawal and standard steroids in de novo renal transplant patients receiving cyclosporine, enteric-coated mycophenolate sodium (EC-MPS, Myfortic1) and basiliximab [abstract]. Transplantation 2006; 82 (Suppl 3): 84-85.
15. Rostaing L, Cantarovich D, Mourad G, et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005; 79:807-814.
16. Vitko S, Klinger M, Salmela K, et al. Two corticosteroid-free regimenstacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study. Transplantation 2005; 80:1734-1741.
17. Woodle ES, Astellas Steroid Withdrawal Study Group. A randomized, double-blinded, placebo-controlled trial of early corticosteroid cessation versus chronic corticosteroids: three year results [abstract]. Transplantation 2006; 82 (Suppl 3):177.
18. Woodle ES, Fujisawa Steroid Withdrawal Study Group. A randomized, double-blinded, placebo-controlled trial of early corticosteroid cessation versus chronic corticosteroid maintenance therapy [abstract]. Am J Transplant 2005; 5 (Suppl 11):54.
19. Gaber AO, Moore LW, Pirsch J, et al. Characteristics of rejection in renal allografts following early corticosteroid withdrawal in a randomized controlled clinical trial: results of 3 year follow-up [abstract]. Transplantation 2006; 82 (Suppl 3):178.
20. Woodle ES, Astellas Steroid Withdrawal Study Group. A randomized, double-blind, placebo-controlled trial of early corticosteroid cessation versus chronic corticosteroids: four year results [abstract]. Am J Transplant 2006; 6 (Suppl 5):177.
21. Laftavi MR, Stephan R, Stefancik B, et al. Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety. Surgery 2005; 137:364-371.
22. Sturdevant ML, Casingal V, Garcia-Roca R, et al. Risk factors for acute rejection (AR) and graft loss (GL) after rapid discontinuation of prednisone [abstract]. Transplantation 2006; 82 (Suppl 3):322.
23. Humar A, Gillingham KJ, Kandaswamy R, et al. A multivariate analysis of risk factors for recurrent acute rejection (AR) in recipients on a steroid avoidance regimen [abstract]. Am J Transplant 2007; 7 (Suppl 2):263.
24. Woodle ES, Gaber AO, Shihab F, et al., Astellas Steroid Withdrawal Study Group. Comparison of T cell depleting and non-T cell depleting antibody induction therapy for early corticosteroid withdrawal regimens [abstract]. Transplantation 2006; 82 (Suppl 3):353.
25. Van de Ham ECH, Kooman JP, Christiaans MHL, et al. Weight changes after renal transplantation: a comparison between patients on 5-mg maintenance steroid therapy and those on steroid-free immunosuppressive therapy. Transpl Int 2003; 16:82-87.
26. Kumar MS, Heifets M, Moritz MJ, et al. Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years. Transplantation 2006; 81:832-839. An important single center experience demonstrating excellent outcomes after early steroid withdrawal in patients subjected to serial protocol biopsies.
27. Gallon LG, Winoto J, Leventhal JR, et al. Effect of prednisone versus no prednisone as part of maintenance immunosuppression on long-term renal transplant function. Clin J Am Soc Nephrol 2006; 1:1029-1038.
28. Pascual J, van Hooff JP, Salmela K, et al. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant. Transplantation 2006; 82:55-61.
29. Ahsan N, Hricik D, Matas A, et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil: a prospective randomized study. Steroid Withdrawal Study Group. Transplantation 1999; 68:1865-1874.
30. Kumar MS, Moritz MJ, Saaed MI, et al. Avoidance of chronic steroid therapy in African American kidney transplant recipients monitored by surveillance biopsy: 1-year results. Am J Transplant 2005; 5:1976-1985.
31. Augustine JJ, Poggio ED, Clemente M, et al. Hemodialysis vintage, black ethnicity, and pretransplantation antidonor cellular immunity in kidney transplant recipients. J Am Soc Nephrol 2007; 18:1602-1606.
32. Hueso M, Boyer J, Seron D, et al. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Transplantation 1998; 66:1727-1731.
33. Houde I, Isenring P, Boucher D, et al. Mycophenolate mofetil, an alternative to cyclosporine A for long-term immunosuppression in kidney transplantation? Transplantation 2000; 70:1251-1253.
34. Weir MR, Ward MT, Blahut SA, et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 4:1567-1573.
35. Mulay AV, Cockfield S, Stryker R, et al. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation 2006; 82:1153-1162. A metaanalysis of randomized and nonrandomized trials of conversion from CNIs to sirolimus.
36. Stallone G, Infante B, Schena A, et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005; 16:3755-3762.
37. Oberbauer R, Schena FP, Wali R, et al. Conversion from calcineurin inhibitors to sirolimus compared with continued use of calcineurin inhibitors in renal allograft recipients: 24-month safety and efficacy results from the CONVERT trial [abstract]. J Am Soc Nephrol 2006; 17:69A.
38. Watson CJE, Firth JE, Williams PF, et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 2005; 5:2496-2503.
39. Baboolal K. Six month interim analysis of a phase III prospective, randomized study to compare conversion from calcineurin inhibitors to rapamycin in established renal allograft recipients with mild to moderate renal insufficiency [abstract]. Am J Transplant 2004; 4 (S8):220.
40. Paczek L, Dedocova J, Matl I, Ohanka E. An open non comparative pilot study of renal function after conversion from cyclosporine to sirolimus in stable renal allograft recipients with mild to moderate renal insufficiency [abstract]. Am J Transplant 2003; 3 (Suppl 5):217.
41. Peddi VR, Jensik S, Pescovitz M, et al. An open-label pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. Clin Transplant 2005; 19:130-136.
42. Wali RK, Richards A, Cunningham R, et al. Can we change the progressive decay in graft function after the onset of chronic allograft nephropathy in the recipients of kidney allografts? [abstract]. Am J Transplant 2003; 3 (S5):336.
43. Moneim HA, Fletchner SM, George P, et al. Conversion to and from sirolimus in renal and hepatic transplant recipients treated with calcineurin inhibitors: effect on renal function [abstract]. Am J Transplant 2005; 5 (S11):376.
44. Hoecker N, Feneberg R, Koepf S, et al. Switch of immunosuppression from calcineurin inhibitors to sirolimus in pediatric renal transplant recipients with CNI toxicity [abstract]. Am J Transplant 2005; 5 (S11):497.
45. Bumbea V, Kamar N, Ribes D, et al. Long term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005; 20:2517-2523.
46. Crowley KL, Hardinger KL, Koch M, et al. A single center experience with sirolimus conversion therapy in renal allograft recipients [abstract]. Am J Transplant 2003; 3 (S5):354.
47. Diekmann F, Waiser J, Fritsche L, et al. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor induced nephrotoxicity. Transplant Proc 2001; 33:3234-3235.
48. Egidi MF, Cowan PA, Naser A, Gaber AO. Conversion to sirolimus in solid organ transplantation: a single-center experience. Transplant Proc 2003; 35:131S-137S.
49. Hadaya K, Wissing M, Broeders N, Abramaowicz D. Nephrotic range proteinuria and other severe adverse events after conversion to sirolimus in renal transplantation: is high exposure to sirolimus responsible? [abstract]. Am J Transplant 2004; 4 (S8):433.
50. Lacha J, Bartosova K, Matl I, et al. Sirolimus associated proteinuria: study in kidney and heart recipients after calcineurin inhibitor withdrawal and in kidney transplant recipients with sirolimus de novo immunosuppression [abstract]. Am J Transplant 2005; 5:414.
51. Wali RK, Mohanlal V, Ramos E, et al. Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant 2007; 7:1572-1583. A large but uncontrolled single-center experience with conversion from CNIs to sirolimus in patients with fairly advanced renal impairment.
52. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 10:1910-1917.
53. Abramowicz D, Manas D, Lao M, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation 2002; 74:1725-1734.
54. Johnson RWG, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72:777-786.
55. Gonwa TA, Hricik DE, Brinker K, et al. Improved renal function in sirolimustreated renal transplant patients after early cyclosporine elimination. Transplantation 2002; 74:1560-1567.
56. Tran HTB, Acharya MK, McKay DB, et al. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. J Am Soc Nephrol 2000; 11:1903-1909.
57. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2002; 71:1282-1287.
58. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67:1036-1042.
59. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69:1252-1260.
60. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74:1070-1076.
61. Larsen TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6:514-522. A randomized single center study showing no benefit in long-term renal function in patients randomized to avoidance of CNIs.